Patents Examined by Changhwa J. Cheu
  • Patent number: 10725048
    Abstract: Disclosed is a method for detecting a test substance, including a first contact step of bringing the test substance, a capturing body 1 that has binding properties to the test substance and is fixed to a substrate, and a capturing body 2 that has binding properties to the test substance and contains a label into contact with each other in a liquid to arrange at least a part of the capturing body 2 on the substrate; after the first contact step, a first dissociation step of dissociating a part of substances containing the capturing body 2 from the substrate and releasing it into the liquid; after the first dissociation step, a second contact step of bringing the test substance, the capturing body 1 that has binding properties to the test substance and is fixed to a substrate, and the capturing body 2 that has binding properties to the test substance and contains a label into contact with each other in the liquid to arrange at least a part of the capturing body 2 on the substrate; after the second contact step,
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: July 28, 2020
    Assignee: SYSMEX CORPORATION
    Inventors: Kenji Akama, Hiroya Kirimura
  • Patent number: 10725050
    Abstract: The present invention is comprised in the field of glycobiology. In particular, it relates to a method for separating, in biological samples, the fraction bound to or associated with sulfated glycosaminoglycans (GAGs), and the applications thereof in biomedicine, such as for identifying the profile of glycoproteins or the profile of lipids bound to or associated with sulfated GAGs, detecting an alteration in the pattern of glycosylation by sulfated GAGs, identifying biomarkers for the diagnosis, for the prognosis, for monitoring the progression of a disease or of the effect of a therapy, or for identifying compounds suitable for the treatment of a disease. The invention also relates to methods for diagnosing mucopolysaccharidosis and for diagnosing and determining the prognosis of a kidney disease.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: July 28, 2020
    Assignees: SERVIZO GALEGO DE SAUDE (SERGAS), UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA
    Inventors: Manuela Alonso Sampedro, Victor Álvarez González, Cristóbal Colón Mejeras, Miguel A. García González, Olaya Lamas González
  • Patent number: 10717977
    Abstract: Methods and compositions for multiplexed protein-protein interaction profiling (e.g., immunoprofiling), based on nucleic acid tagging of polypeptides (e.g., by RNA display) are described. In some embodiments the described compositions and methods utilize a library of prey polypeptide targets linked to prey RNAs encoding them, and a population of bait polypeptides, e.g., a mixture of antibodies, that bind to one or more of the prey polypeptide targets and are used to isolate and identify the bound prey polypeptide targets by amplification of their associated prey RNAs and sequencing of the corresponding cDNAs. In other embodiments the prey polypeptide targets are linked to DNA Bar Codes, which serve as unique identifiers of the tagged polypeptide.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: July 21, 2020
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventor: Joshua LaBaer
  • Patent number: 10718763
    Abstract: Platform technology involving aqueous microdroplet reaction vessels created, arrayed, and characterized by imaging microscopy in a microfluidic device are applied to a wide variety of bioassays involving the detection and phenotypic characterization of single cells. The bioassays include the rapid and automated detection of microbial pathogens and their antibiotic sensitivity from patient samples as well as the characterization of immune responses using a patient's own cells, including the killing of tumor cells.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 21, 2020
    Assignee: Northeastern University
    Inventors: Tania Konry, Pooja Sabhachandani, Saheli Sarkar
  • Patent number: 10712322
    Abstract: The present invention provides methods for analyzing compositions of polypeptides such as antibodies by ionic strength-mediated pH gradient ion exchange chromatography. In some aspects, the methods use a combination of pH gradients and ionic strength gradients to separate the polypeptide from charge variants of the polypeptide. In some aspects, the methods use a stable ionic strength to optimize the pH gradient separation window to separate the polypeptide from charge variants. Such methods are useful for analyzing polypeptide, e.g. antibodies, with a pI greater than 9 or a pI less than 7. In some aspects, the invention provides a multiproduct method for the analysis of polypeptides of varying pI's.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Yajun Wang, George Tony Moreno, Boyan Zhang, Liangyi Zhang, Dell Farnan, Thomas Patapoff
  • Patent number: 10705097
    Abstract: Provided herein are methods and devices for the detection of conditions or disorders by detecting altered levels of stress response pathway biomarkers. Also provided are methods and reagents for identifying panels of biomarkers associated with a condition or disorder.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: July 7, 2020
    Assignee: Gaia Medical Institute
    Inventor: Sarka O. Southern
  • Patent number: 10690664
    Abstract: This invention relates generally to devices and methods for performing optical and electrochemical assays and, more particularly, to test devices, e.g., cartridges, methods and systems, wherein the test devices have an entry port configured to receive a test sample into a holding chamber; a first conduit having at least one lateral flow test strip; and a displacement device, such as a pneumatic pump, configured to move a portion of said test sample from said holding chamber into said first conduit. The present invention is particularly useful for performing immunoassays and/or electrochemical assays at the point-of-care.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: June 23, 2020
    Assignee: Abbott Point of Care Inc.
    Inventors: Pierre Emeric, Graham Davis, Thomas Ewart, Sergey Gershtein
  • Patent number: 10690573
    Abstract: The present disclosure provides methods for reducing the viscosity of a cell lysate or tissue lysate by: contacting the cell lysate or tissue lysate with a compressible and open-cell foam filter having a pore size from about 0.65 mm to about 1.22 mm, compressing the filter to recover the lysate absorbed in the filter, and collecting the filtered lysate; and also provides kits therefor.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: June 23, 2020
    Assignee: Cytoskeleton, Inc.
    Inventors: Kim Middleton, Soonjin Hong, Wai K. Law, Henrick Horita
  • Patent number: 10677795
    Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also referred to as scleroderma; SSc) and the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices, and test kits which comprise these markers, and also to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc subgroups.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: June 9, 2020
    Assignee: Protagen AG
    Inventors: Petra Budde, Dieter Zucht, Angelika Lüking, Matthias Schneider
  • Patent number: 10670587
    Abstract: The present invention provides a cellular system for the detection of the presence of one or more antibody species in sample, preferably a serum or plasma sample. The method is in particular useful for the analysis of patients who have been sensitized against blood group antigens expressed on erythrocytes, platelets or granulocytes. The system uses fluorescence labeled cells specific for each antigen and hence, for each antibody species. Provided are the methods, system and diagnostic kits for performing the methods of the invention. In addition, the present invention discloses a method for removing antibodies from a sample such as a serum sample. Such a method is useful for absorbing antibodies from poly-agglutinating sera.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: June 2, 2020
    Assignees: DRK-Blutspendedienst Baden-Wuerttemberg-Hessen gGmgH, Johann Wolfgang Goethe-Universitaet Frankfurt am Main
    Inventors: Halvard Boenig, Christof Geisen, Eliza Justyna Wiercinska, Nikolas Ryschka
  • Patent number: 10663464
    Abstract: The present technology regards the utilization of CEACAM1 as a biomarker for cancer. In particular the present invention regards the detection and measurement of soluble CEACAM1 levels for the detection and diagnosis of melanoma.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: May 26, 2020
    Inventor: Gal Markel
  • Patent number: 10648978
    Abstract: Identification of autoantibodies associated with Crohn's disease useful in diagnosis and management using an innovative protein array technology, namely nucleic acid programmable protein arrays (NAPPA) and applications relating thereto. Overall, reactivity of IgG autoantibodies was stronger than that of IgA autoantibodies; however, IgA autoantibodies showed greater differential reactivity between cases and controls. Four IgA autoantibodies against SNRPB, PRPH, PTTG1 and SNAI1 were newly identified with sensitivities above 15% at 95% specificity, among which anti-SNRPB-IgA had the highest sensitivity of 24.0%. Autoantibodies associated with specific disease subtypes were also found.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: May 12, 2020
    Assignees: Mayo Foundation for Medical Education and Research, Arizona Board of Regents on behalf of Arizona State University
    Inventors: Haoyu Wang, Ji Qiu, Joshua LaBaer, Jonathan Leighton, Shabana Pasha
  • Patent number: 10634684
    Abstract: An object of the present invention is to provide a method for efficiently identifying a polyubiquitinated substrate which is generally not easily identified. The method for identifying a polyubiquitinated substrate includes (1) a step of expressing a trypsin-resistant polyubiquitin chain-binding protein and a ubiquitin ligase in a cell, (2) a step of isolating a complex that contains the trypsin-resistant polyubiquitin chain-binding protein from the cell having undergone the step (1), (3) a step of subjecting the complex isolated by the step (2) to trypsin digestion, and (4) a step of identifying a peptide that has a ubiquitination site from a digested material obtained by the step (3).
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 28, 2020
    Assignee: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Yukiko Yoshida, Yasushi Saeki, Hikaru Tsuchiya, Arisa Murakami, Keiji Tanaka
  • Patent number: 10634680
    Abstract: Split enzyme reporter systems are disclosed for detecting an analyte in a mixture. Fragments of the split enzyme may be covalently bound to targeting domains that bind to target regions of an analyte, thereby causing formation of an active complex. Some split enzyme reporter systems can be used to detect an analyte without the use of analyte immobilization, blocking, or wash steps. Some reporter systems also enable rapid detection of the analyte of interest.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: April 28, 2020
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Andrew S. Dixon, Shawn Owen, Julio C. Delgado
  • Patent number: 10620220
    Abstract: The invention provides a method detecting free light chains (FLCs) comprising: (i) providing a sample from a subject; (ii) mixing the sample with an anti-FLC specific antibody, or fragments thereof capable of specifically binding the FLC, to form a mixture; (iii) passing the mixture through a capillary tube by capillary zone electrophoresis (CZE); and (iv) detecting the presence of the antibody or fragment thereof after passage through at least a portion of the capillary tube. Capillary tubes for use in CZE and kits comprising capilliary tubes and at least one anti-FLC antibody are also provided.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: April 14, 2020
    Assignee: The Binding Site Limited
    Inventor: Graham Peter Mead
  • Patent number: 10620191
    Abstract: A device for incubating an immunoblot strip (6) includes at least one incubation channel (1) into which an elongate immunoblot strip (6) having at least one biological material on its front is inserted with its back facing a channel base (2). An agitating means (7), with which the immunoblot strip (6) is agitatable around a transverse axis (8) of the strip (6) at least at times during incubation via an agitating device (7). For handling and/or grouping incubation channels (1) with immunoblot strips (6) inserted, a rack (3) for taking up at least two incubation channels (1) is provided. The rack (3) is in operative connection with said agitating means (7) via load transmission points.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: April 14, 2020
    Assignee: Euroimmun Medizinische Labordiagnostika AG
    Inventors: Winfried Stöcker, Wolfgang Meyer, Thomas Scheper, Antje Euken
  • Patent number: 10613083
    Abstract: A biosensor system for the detection of target analytes that includes a living biological cell of a predetermined type; a signal-generating reporter associated with the living biological cell; a signal transduction pathway or other activator mechanism or means associated with the signal-generating reporter; a universal detector element associated with the activator mechanism; and an analyte binding element associated with the universal detector element, wherein the analyte binding element is specific to both the universal detector element and a target analyte.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 7, 2020
    Assignee: Fundamental Solutions Corporation
    Inventors: Thomas J. Zupancic, Joseph D. Kittle, Lingchun Zeng, Srikanth Vedamoorthy, Richard S. Brody, Marvin R. Williams
  • Patent number: 10613102
    Abstract: The present invention is based on the finding that red blood cell antigens can be exploited as a means to detect red blood cells/erythrocytes. Specifically, by identifying red blood cell antigens which are expressed by substantially all red blood cell types, it is possible to provide a method which achieves the reliable detection of red blood cells.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: April 7, 2020
    Assignee: QBD (QS-IP) Limited
    Inventors: Janine Scott Robb, Andrew Gordon Robb, David Cooper Robson
  • Patent number: 10613100
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, and of anti-oxMIF antibodies in tissues. A detection method is provided which uses immunohistochemistry or immunofluorescence and wherein specific anti-oxMIF antibodies and specific idiotypic monoclonal rabbit antibodies are used.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: April 7, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Alexander Schinagl, Michael Thiele, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • Patent number: 10577640
    Abstract: The disclosure provides methods for detecting the concurrent presence of at least two targets within a biological sample. The method includes contacting said biological sample with a first binding agent, said first binding agent operably linked to a first sortase molecule, wherein said first binding agent specifically binds to a first target; contacting said biological sample with a second binding agent, said second binding agent operably linked to a first sortase recognition sequence peptide, wherein said second binding agent specifically binds to a second target; adding a sortase substrate under conditions where a first sortase-mediated ligation of the sortase substrate to the first sortase recognition sequence will produce a ligation product, and detecting the ligation product wherein detection of said ligation product indicates the concurrent presence of the first target and the second target in the biological sample. Also disclosed are kits comprising reagents for performing the methods as claimed.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: March 3, 2020
    Assignee: CELL SIGNALING TECHNOLOGY, INC.
    Inventors: Khanh Duc Huynh, Wan Cheung Cheung, Roberto Polakiewicz